Tremor & Dystonia
Tremor and dystonia management spans medication, botulinum toxin and neurosurgery with major recent advances. The session covers essential tremor pharmacotherapy (propranolol, primidone, topiramate, gabapentin), focused ultrasound thalamotomy (ExAblate Neuro), deep brain stimulation for tremor (Vim) and dystonia (GPi), dystonia botulinum toxin protocols (cervical, focal, hemifacial spasm), tardive dyskinesia treatment with VMAT2 inhibitors (valbenazine, deutetrabenazine), Wilson's disease management, and emerging therapies. Discussion addresses Holmes tremor, drug-induced tremor differentiation, focused ultrasound for bilateral indications and pallidotomy, neuromodulation programming for tremor, the role of physiotherapy in tremor management, and pediatric movement disorders.
- Essential tremor pharmacology
- Focused ultrasound thalamotomy
- DBS for tremor and dystonia
- Botulinum toxin protocols
- VMAT2 inhibitors (valbenazine)
- Wilson's disease
- Holmes tremor
- Pediatric movement disorders
Explore the full GCNN 2027 program
- 01Stroke & Cerebrovascular Disease
- 02Alzheimer’s & Dementia
- 03Multiple Sclerosis
- 04Parkinson’s & Movement Disorders
- 05Epilepsy
- 06Neuromuscular Disease
- 07Headache Medicine
- 08Neuro-Oncology
- 09Clinical Neuroscience & AI
- 10Spinal Cord Injury
- 11Traumatic Brain Injury
- 12Sleep Disorders
- 13Neuropathic Pain
- 14Cerebellar & Ataxia Disorders
- 15Functional Neurological Disorders
- 16Pediatric Neurology
- 17Neuroimmunology
- 18Brain-Computer Interfaces
- 19Migraine
- 20Cluster Headache
- 21Dementia with Lewy Bodies
- 22Frontotemporal Dementia
- 23Huntington Disease
- 24ALS
- 26Restless Legs Syndrome
- 27Neuroinfectious Disease
- 28Brain Tumors
- 29Vestibular Disorders
- 30Autonomic Disorders
- 31Functional Imaging
- 32Neuro-Ophthalmology
- 33Neuropsychology
- 34Movement Disorder Surgery
- 35Genetic Counselling